Skip to main content
SpringerLink
Log in

Matrix metalloproteinases in colorectal cancer: Is it worth talking about?

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases (MMPs), a family of extracellular matrix degrading enzymes, are expressed in various stages of colorectal cancer (CRC) and correlate with survival and prognosis. There is considerable evidence in preclinical models that MMP inhibitors (MMPIs) are effective at multiple stages of CRC tumor progression, including reducing the number of intestinal adenomas, inhibiting the growth and establishment of primary CRC tumors, and reducing metastasis to the lung and liver. However, clinical trials with MMPIs in other tumor types have been largely unsuccessful, raising the question as to whether MMPs represent therapeutic targets in CRC. This review focuses on the expression, role, and contribution of MMP family members to various stages of CRC tumor progression. The conclusion is that there is considerable evidence to suggest that MMP inhibition may be an effective strategy if applied at either end of the tumor progression spectrum; the prevention of adenomas, or the treatment of micrometastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O'Brien MJ, Winawer SJ, Zauber AG, Gottlieb LS, Sternberg S, Diaz B, Dickersin GR, Ewing S, Geller S, Kasimian D, Komorowski R, Szporn A: The National Polyp Study Workshop: The national polyp study: Patient and polyp characteristics associated with high grade dysplasia in colorectal adenomas. J Natl Cancer Inst 98: 371–379, 1990

    Google Scholar 

  2. Willert K, Nusse R: Beta-catenin: A key mediator of Wnt signaling. Curr Opin Genet Dev 8: 95–102, 1998

    Google Scholar 

  3. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382: 638–642, 1996

    Google Scholar 

  4. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science 275: 1784–1787, 1997

    Google Scholar 

  5. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522–5527, 1999

    Google Scholar 

  6. Koh TJ, Bulitta CJ, Fleming JV, Dockray GJ, Varro A, Wang TC: Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 106: 533–539, 2000

    Google Scholar 

  7. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T, Miki Y, Mori T, Nakamura Y: Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1: 229–233, 1992

    Google Scholar 

  8. Groden J, Thilveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M, Sargeant L, Krapcho K, Wolf E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, Le Paslier D, Abderrahim H, Cohen D, Leppert M, White R: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66: 589–600, 1991

    Google Scholar 

  9. Bos JL, Fearon ER, Hamilton SR, Verlaan-deVries M, vanBloom JH: Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293–297, 1987

    Google Scholar 

  10. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49–53, 1991

    Google Scholar 

  11. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ: Identification of a gene located at chromosome5q21 that is mutated in colorectal cancers. Science 251: 1366–1370, 1991

    Google Scholar 

  12. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW, Vogelstein B: Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247: 49–59, 1990

    Google Scholar 

  13. Dursun A, Akyurek N, Gunel N, Yamac D: Prognostic implication of nm23-H1 expression in colorectal carcinomas. Pathology 34: 427–432, 2002

    Google Scholar 

  14. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463–516, 2001

    Google Scholar 

  15. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Ins 89: 1260–1270, 1997

    Google Scholar 

  16. Gross J, Lapiere CM: Collagenolytic activity in amphibian tissues: A tissue culture assay. Proc Natl Acad Sci USA 48: 1014–1022, 1962

    Google Scholar 

  17. Hidalgo M, Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93: 178–193, 2001

    Google Scholar 

  18. Crabbe T, Willenbrock F, Eaton D, Hynds P, Carne AF, Murphy G, Docherty AJP: Biochemical characterization of matrilysin Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases. Biochemistry 31: 8500–8507, 1992

    Google Scholar 

  19. Wang X, Pei D: Shedding of membrane type matrix metalloproteinase 5 by a furin-type convertase: A potential mechanism for down-regulation. J Biol Chem 276: 35953–35960, 2001

    Google Scholar 

  20. Kang T, Nagase H, Pei D: Activation of membrane-type matrix metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-Golgi network. Cancer Res 62: 675–681, 2002

    Google Scholar 

  21. Rhee JS, Coussens LM: RECKing MMP function: Implications for cancer development. Trends Cell Biol 12: 209–211, 2002

    Google Scholar 

  22. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759–767, 1990

    Google Scholar 

  23. Goss KJ, Brown PD, Matrisian LM: Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 78: 629–635, 1998

    Google Scholar 

  24. Stetler-Stevenson WG, Hewitt R, Corcoran M: Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Seminars in Cancer Biol 7: 147–154, 1996

    Google Scholar 

  25. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67–68, 1980

    Google Scholar 

  26. Nakajima M, Welch DR, Belloni PN, Nicolson GL: Degradation of basement membrane type IV collagen and lug subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 47: 4869–4876, 1987

    Google Scholar 

  27. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277: 225–228, 1997

    Google Scholar 

  28. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y: Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyzes and transforming growth factor-beta 1 release. Biochem J 322: 809–814, 1997

    Google Scholar 

  29. Coussens LM, Werb Z: Inflammatory cells and cancer. Think different! J Exp Med 193: F23–F26, 2001

    Google Scholar 

  30. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ: Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139: 1861–1872, 1997

    Google Scholar 

  31. Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M: Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114: 111–118, 2001

    Google Scholar 

  32. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163–176, 2000

    Google Scholar 

  33. Schonbeck U, Mach F, Libby P: Generation of biologically active IL-1 beta by matrix metalloproteinases: A novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 161: 3340–3346, 1998

    Google Scholar 

  34. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H: Matrix metalloproteinases degrade insulin-like growth factorbinding protein-3 in dermal fibroblast cultures. J Biol Chem 269: 25742–25746, 1994

    Google Scholar 

  35. Thrailkill KM, Quarles LD, Nagase H, Suzuki K, Serra DM, Fowlkes JL: Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology 136: 3527–3533, 1995

    Google Scholar 

  36. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH: A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 61: 237–242, 2001

    Google Scholar 

  37. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I, Miao HQ, Ma YS: Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 93: 7069–7074, 1996

    Google Scholar 

  38. Boudreau N, Sympson CJ, Werb Z, Bissell MJ: Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267: 891–893, 1995

    Google Scholar 

  39. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182: 1777–1783, 1995

    Google Scholar 

  40. Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM: Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 105: 143–150, 2000

    Google Scholar 

  41. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements JM, Crimmin M, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K: Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol 57: 774–777, 1995

    Google Scholar 

  42. Newell KJ, Witty JP, Rodgers WH, Matrisian LM: Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 10: 199–206, 1994

    Google Scholar 

  43. Yang W, Arii S, Gorrin-Rivas MJ, Mori A, Onodera H, Imamura M: Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer 91: 1277–1283, 2001

    Google Scholar 

  44. Zeng ZS, Huang Y, Cohen AM, Guillem JG: Prediction of colorectal cancer relapse and survival via tissue rna levels of matrix metalloproteinase-9. J Clin Oncol 14: 3133–3140, 1996

    Google Scholar 

  45. Adachi Y, Yamamoto H, Itoh F, Arimura Y, Nishi M, Endo T, Imai K: Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. Int. J Cancer 95: 290–294, 2001

    Google Scholar 

  46. Shiozawa J, Ito M, Nakayama T, Nakashima M, Kohno S, Sekine I: Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol 13: 925–933, 2000

    Google Scholar 

  47. Brand K: Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr Gene Ther 2: 255–271, 2002

    Google Scholar 

  48. Conradi RA, Hilgers AR, Ho NF, Burton PS: The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharm Res 9: 435–439, 1992

    Google Scholar 

  49. Caputo CB, Wolanin DJ, Roberts RA, Sygowski LA, Patton SP, Caccese RG, Shaw A, DiPasquale G: Proteoglycan degradation by a chondrocyte metalloprotease. Effects of synthetic protease inhibitors. Biochem Pharmacol 36: 995–1002, 1987

    Google Scholar 

  50. Hanemaaijer R, Visser H, Koolwijk P, Sorsa T, Salo T, Golub LM, van Hinsbergh VW: Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 12: 114–118, 1998

    Google Scholar 

  51. Ryan ME, Ramamurthy S, Golub LM: Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol 3: 85–96, 1996

    Google Scholar 

  52. Takeuchi N, Ichikawa T, Momiyama N, Hasegawa S, Nagashima Y, Miyazaki K, Koshikawa N, Mitsuhashi M, Shimada H: Matrilysin gene expression in sporadic and familial colorectal adenomas. Mol Carcinog 19: 225–229, 1997

    Google Scholar 

  53. Moser AR, Pitot HC, Dove WF: A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247: 322–324, 1990

    Google Scholar 

  54. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF: Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 668–670, 1992

    Google Scholar 

  55. Wilson CL, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 94: 1402–1407, 1997

    Google Scholar 

  56. Wagenaar-Miller RA, Hanley G, Shattuck-Brandt RL, DuBois RN, Bell RN, Matrisian LM, Morgan DW: Cooperative effects of matrix metalloproteinase and cycloxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer 88: 1445–1452, 2003

    Google Scholar 

  57. Boulay A, Masson R, Chenard MP, El Fahime M, Cassard L, Bellocq JP, Sautes-Fridman C, Basset P, Rio MC: High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res 61: 2189–2193, 2001

    Google Scholar 

  58. Blavier L, Henriet P, Imren S, DeClerck YA: Tissue inhibitors of matrix metalloproteinases in cancer. Ann NY Acad Sci 878: 108–119, 1999

    Google Scholar 

  59. Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21: 2245–2252, 2002

    Google Scholar 

  60. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54: 4726–4728, 1994

    Google Scholar 

  61. An ZL, Wang XE, Willmott N, Chander SK, Tickle S, Docherty AJP, Mountain A, Millican AT, Morphy R, Porter JR, Epemolu RO, Kubota T, Moossa AR, Hoffman RM: Conversion of highly malignant colon cancer from an aggressive to a controled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis 15: 184–195, 1997

    Google Scholar 

  62. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S: Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59: 1252–1258, 1999

    Google Scholar 

  63. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 878: 236–270, 1999

    Google Scholar 

  64. Witty JP, McDonnell S, Newell K, Cannon P, Navre M, Tressler R, Matrisian LM: Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 54: 4805–4812, 1994

    Google Scholar 

  65. Shah V, Kumar S, Zirvi KA: Metastasis of human colon tumor cells in vivo: Correlation with the overexpression of plasminogen activators and 72 kDa gelatinase. In Vivo 8: 321–326,1994

    Google Scholar 

  66. Hasegawa S, Koshikawa N, Momiyama N, Moriyama K, Ichikawa Y, Ishikawa T, Mitsuhashi M, Shimada H, Miyazaki K: Matrilysin-specific oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 76: 812–816, 1998

    Google Scholar 

  67. Ohno I, Ohtani H, Nitta Y, Suzuki J, Hoshi H, Honma M, Isoyama S, Tanno Y, Tamura G, Yamauchi K, Nagura H, Shirato K: Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 16: 212–219, 1997

    Google Scholar 

  68. Oba K, Konno H, Tanaka T, Baba M, Kamiya K, Ohta M, Kaneko T, Shouji T, Igarashi A, Nakamura S: Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166. Cancer Lett 175: 45–51, 2002

    Google Scholar 

  69. Maki H, Hojo K, Tanaka H, Sawada TY, Maekawa R, Yoshioka T: Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11. Clin Exp Metastasis 19: 519–526, 2002

    Google Scholar 

  70. Primrose JN, Bleiberg H, Daniel F, Van Belle S, Mansi JL, Seymour M, Johnson PW, Neoptolemos JP, Baillet M, Barker K, Berrington A, Brown PD, Millar AW, Lynch KP: Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer 79: 509–514, 1999

    Google Scholar 

  71. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4: 1101–1109, 1998

    Google Scholar 

  72. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol 19: 3447–3455, 2001

    Google Scholar 

  73. Gore M, A'Hern R, Stankiewicz M, Slevin M: Tumour marker levels during marimastat therapy. Lancet 348: 263–264, 1996

    Google Scholar 

  74. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18: 1135–1149, 2000

    Google Scholar 

  75. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295: 2387–2392, 2002

    Google Scholar 

  76. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW: Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial. Br J Cancer 86: 1864–1870, 2002

    Google Scholar 

  77. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA: A double-blind placebo-controled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161–167, 2002

    Google Scholar 

  78. Bayer Corporation: Bayer Halts Clinical Trials Evaluating MMPI. http://www. bayerpharma-na. com/company/ co0221. asp 1999

  79. Moore MJ, Hamm J, Eisenberg P, Dagenais M, Hagan K, Fields A, Greenberg B, Schwartz B, Ottaway J, Zee B, Seymour L: Acomparison between gemcitabine(GEM)and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients with advanced pancreatic cancer (abstr 930). Proc Am Soc Clin Oncol 19, 240a. 2000.

    Google Scholar 

  80. Hulboy DL, Rudolph LA, Matrisian LM: Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod 3: 27–45, 1997

    Google Scholar 

  81. Woessner JF, Jr.: The matrix metalloproteinase family. In Parks WC and Mecham RP, eds. Matrix metalloproteinases. Academic Press, San Diego, pp. 1–14, 1998

    Google Scholar 

  82. Rudolph-Owen LA, Hulboy DL, Wilson CL, Mudgett J, Matrisian LM: Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology 138: 4902–4911, 1997

    Google Scholar 

  83. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in APC delta 716 knockout mice by inhbition of cyclooxygenase 2 (COX-2). Cell 87: 803–809, 1996

    Google Scholar 

  84. Hawk E, Lubet R, Limburg P: Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86: 2551–2563, 1999

    Google Scholar 

  85. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946–1952, 2000

    Google Scholar 

  86. Arihiro S, Ohtani H, Hiwatashi N, Torii A, Sorsa T, Nagura H: Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology 39: 50–59, 2001

    Google Scholar 

  87. Baker EA, Bergin FG, Leaper DJ: Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 87: 1215–1221, 2000

    Google Scholar 

  88. McKerrow JH, Bhargava V, Hansell E, Huling S, Kuwahara T, Matley M, Coussens L, Warren R: A functional proteomics screen of proteases in colorectal carcinoma. Mol Med 6: 450–460, 2000

    Google Scholar 

  89. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S: Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47: 63–73, 2000

    Google Scholar 

  90. Heuschkel RB, Macdonald TT, Monteleone G, Bajaj-Elliott M, Smith JA, Pender SL: Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 47: 57–62, 2000

    Google Scholar 

  91. Gray ST, Yun K, Motoori T, Kuys YM: Interstitial collagenase gene expression in colonic neoplasia. Am J Pathol 143: 663–671, 1993

    Google Scholar 

  92. Yantiss RK, Bosenberg MW, Antonioli DA, Odze RD: Utility of MMP-1, p53, E-cadherin, and collagen IV immunohistochemical stains in the differential diagnosis of adenomas with misplaced epithelium versus adenomas with invasive adenocarcinoma. Am J Surg Pathol 26: 206–215, 2002

    Google Scholar 

  93. Papadopoulou S, Scorilas A, Arnogianaki N, Papapanayiotou B, Tzimogiani A, Agnantis N, Talieri M: Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumor Biol 22: 383–389, 2001

    Google Scholar 

  94. Otani Y, Okazaki I, Arai M, Kameyama K, Wada N, Maruyama K, Yoshino K, Kitajima M, Hosoda Y, Tsuchiya M: Gene expression of interstitial collagenase (matrix metalloproteinase 1) in gastrointestinal tract cancers. J Gastroenterol 29: 391–397, 1994

    Google Scholar 

  95. Murray GI, Duncan ME, Oneil P, Melvin WT, Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461–462, 1996

    Google Scholar 

  96. Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB, Urist MM: Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg 233: 786–792, 2001

    Google Scholar 

  97. Roeb E, Dietrich CG, Winograd R, Arndt M, Breuer B, Fass J, Schumpelick V, Matern S: Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9. Cancer 92: 2680–2691, 2001

    Google Scholar 

  98. Murashige M, Miyahara M, Shiraishi N, Saito T, Kohno K, Kobayashi M: Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol 26: 303–309, 1996

    Google Scholar 

  99. Kikuchi R, Noguchi T, Takeno S, Kubo N, Uchida Y: Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. Br J Cancer 83: 215–218, 2000

    Google Scholar 

  100. Kim TS, Kim YB: Correlation between expression of matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) and angiogenesis in colorectal adenocarcinoma. J Korean Med Sci 14: 263–270, 1999

    Google Scholar 

  101. Ring P, Johansson K, Hoyhtya M, Rubin K, Lindmark G: Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer-a predictor of tumor stage. Br J Cancer 76: 805–811, 1997

    Google Scholar 

  102. Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rogers L, Stamp GWH: Stromal expression of 72 kDa Type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 141: 389–396, 1992

    Google Scholar 

  103. Bodey B, Bodey B Jr., Siegel SE, Kaiser HE: Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas. In Vivo 14: 659–666, 2000

    Google Scholar 

  104. Ohtani H, Motohashi H, Sato H, Seiki M, Nagura H: Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy. Int J Cancer 68: 565–570: 1996

    Google Scholar 

  105. Louis E, Ribbens C, Godon A, Franchimont D, De Groote D, Hardy N, Boniver J, Belaiche J, Malaise M: Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 120: 241–246, 2000

    Google Scholar 

  106. Thewes M, Pohlmann G, Atkinson M, Mueller J, Putz B, Hofler H: Stromelysin-3 (st-3) mRNA expression in colorectal carcinomas: Localization and clinicopathologic correlations. Diagn Mol Pathol 5: 284–290, 1996

    Google Scholar 

  107. Malhotra S, Newman E, Eisenberg D, Scholes J, Wieczorek R, Mignatti P, Shamamian P: Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer: A possible mechanism of neoplastic progression. Dis Colon Rectum 45: 537–543, 2002

    Google Scholar 

  108. McDonnell S, Navre M, Coffey RJ, Matrisian LM: Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 4: 527–533, 1991

    Google Scholar 

  109. Newell KJ, Matrisian LM, Driman DK: Matrilysin (Matrix metalloproteinase-7) expressin in ulcerative colitis-related tumorigenesis. Mol Carcinog 34: 59–63, 2002

    Google Scholar 

  110. Nagashima Y, Hasegawa S, Koshikawa N, Taki A, Ichikawa Y, Kitamura H, Misugi K, Kihira Y, Matuo Y, Yasumitsu H, Miyazaki K: Expression of matrilysin in vascular endothelial cells adjacent to matrilysin-producing tumors. Int J Cancer 72: 441–445, 1997

    Google Scholar 

  111. Masaki T, Matsuoka H, Sugiyama M, Abe N, Goto A, Sakamoto A, Atomi Y: Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 84: 1317–1321, 2001

    Google Scholar 

  112. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K: Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 45: 252–258, 1999

    Google Scholar 

  113. Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H: Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: A novel approach from immune/inflammatory aspect. Jpn J Cancer Res 88: 72–81, 1997

    Google Scholar 

  114. Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, Dano K: 92 kda type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 65: 57–62, 1996

    Google Scholar 

  115. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P, Gespach C: Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 64: 70–75, 1995

    Google Scholar 

  116. Leeman MF, McKay JA, Murray GI: Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 55: 758–762, 2002

    Google Scholar 

  117. Zeng ZS, Cohen AM, Zhang ZF, Stetlerstevenson W, Guillem JG: Elevated tissue inhibitor of metalloproteinase 1RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1: 899–906, 1995

    Google Scholar 

  118. Powe DG, Brough JL, Carter GI, Bailey EM, Stetlerstevenson WG, Turner DR, Hewitt RE: Timp-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer 75: 1678–1683, 1997

    Google Scholar 

  119. Zeng Z, Sun Y, Shu W, Guillem JG: Tissue inhibitor of metalloproteinase-3 is a basement membrane-associated protein that is significantly decreased in human colorectal cancer. Dis Colon Rectum 44: 1290–1296, 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cancer Biology, Vanderbilt University, 771 Preston Research Building, 23rd and Pierce Avenue, Nashville, TN, 37232

    Rebecca A. Wagenaar-Miller, Lee Gorden & Lynn M. Matrisian

Authors
  1. Rebecca A. Wagenaar-Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lee Gorden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lynn M. Matrisian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lynn M. Matrisian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wagenaar-Miller, R.A., Gorden, L. & Matrisian, L.M. Matrix metalloproteinases in colorectal cancer: Is it worth talking about?. Cancer Metastasis Rev 23, 119–135 (2004). https://doi.org/10.1023/A:1025819214508

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1025819214508

Search

Navigation